Our results suggest that ASC-J9® not only suppresses the PCa progression via degrading AR, but it can also alter the ATF3/PTK2 signaling to suppress the PCa progression in an AR-independent manner. The gene discussed is PTK2; the disease is posterior cortical atrophy.